240 related articles for article (PubMed ID: 27044648)
1. Levodopa therapy for Parkinson disease: A look backward and forward.
LeWitt PA; Fahn S
Neurology; 2016 Apr; 86(14 Suppl 1):S3-12. PubMed ID: 27044648
[TBL] [Abstract][Full Text] [Related]
2. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
Lees AJ; Tolosa E; Olanow CW
Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
[TBL] [Abstract][Full Text] [Related]
3. The medical treatment of Parkinson disease from James Parkinson to George Cotzias.
Fahn S
Mov Disord; 2015 Jan; 30(1):4-18. PubMed ID: 25491387
[TBL] [Abstract][Full Text] [Related]
4. New levodopa therapeutic strategies.
LeWitt PA
Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1():S37-40. PubMed ID: 26459662
[TBL] [Abstract][Full Text] [Related]
5. Classics in chemical neuroscience: levodopa.
Whitfield AC; Moore BT; Daniels RN
ACS Chem Neurosci; 2014 Dec; 5(12):1192-7. PubMed ID: 25270271
[TBL] [Abstract][Full Text] [Related]
6. Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease.
Storch A; Wolz M; Beuthien-Baumann B; Löhle M; Herting B; Schwanebeck U; Oehme L; van den Hoff J; Perick M; Grählert X; Kotzerke J; Reichmann H
Neurology; 2013 May; 80(19):1754-61. PubMed ID: 23576623
[TBL] [Abstract][Full Text] [Related]
7. Levodopa delivery systems: advancements in delivery of the gold standard.
Ngwuluka N; Pillay V; Du Toit LC; Ndesendo V; Choonara Y; Modi G; Naidoo D
Expert Opin Drug Deliv; 2010 Feb; 7(2):203-24. PubMed ID: 20095943
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M
Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756
[TBL] [Abstract][Full Text] [Related]
9. Dopa-responsive, nonprogressive juvenile parkinsonism: report of a case.
Rajput A; Kishore A; Snow B; Bolton CF; Rajput AH
Mov Disord; 1997 May; 12(3):453-6. PubMed ID: 9159748
[No Abstract] [Full Text] [Related]
10. [Clinical studies with levodopa/carbidopa intestinal gel].
Klivényi P; Vécsei L
Ideggyogy Sz; 2014 Jan; 67(1-2):5-8. PubMed ID: 24654442
[TBL] [Abstract][Full Text] [Related]
11. Targeting striatal metabotropic glutamate receptor type 5 in Parkinson's disease: bridging molecular studies and clinical trials.
Vallano A; Fernandez-Duenas V; Garcia-Negredo G; Quijada MA; Simon CP; Cuffí ML; Carbonell L; Sanchez S; Arnau JM; Ciruela F
CNS Neurol Disord Drug Targets; 2013 Dec; 12(8):1128-42. PubMed ID: 24040811
[TBL] [Abstract][Full Text] [Related]
12. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
Rascol O
Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
[TBL] [Abstract][Full Text] [Related]
13. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia.
Stacy M; Galbreath A
Clin Neuropharmacol; 2008; 31(1):51-6. PubMed ID: 18303491
[TBL] [Abstract][Full Text] [Related]
14. Levodopa therapeutics for Parkinson's disease: new developments.
LeWitt PA
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S31-4. PubMed ID: 19131040
[TBL] [Abstract][Full Text] [Related]
15. [Dopamine agonists in the therapy of parkinson syndrome].
Kapfhammer HP; Rüther E
Nervenarzt; 1985 Feb; 56(2):69-81. PubMed ID: 3982566
[No Abstract] [Full Text] [Related]
16. Targeting adenosine A2A receptors in Parkinson's disease.
Schwarzschild MA; Agnati L; Fuxe K; Chen JF; Morelli M
Trends Neurosci; 2006 Nov; 29(11):647-54. PubMed ID: 17030429
[TBL] [Abstract][Full Text] [Related]
17. Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.
Asanuma M; Miyazaki I; Diaz-Corrales FJ; Shimizu M; Tanaka K; Ogawa N
Neurol Res; 2005 Jul; 27(5):533-9. PubMed ID: 15978181
[TBL] [Abstract][Full Text] [Related]
18. Treatments for Parkinson disease--past achievements and current clinical needs.
Poewe W
Neurology; 2009 Feb; 72(7 Suppl):S65-73. PubMed ID: 19221317
[TBL] [Abstract][Full Text] [Related]
19. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
Olanow CW
Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
[TBL] [Abstract][Full Text] [Related]
20. Parkinsonism: candidate disorder for implanted pumps?
Nutt JG
Ann N Y Acad Sci; 1988; 531():194-9. PubMed ID: 2898229
[No Abstract] [Full Text] [Related]
[Next] [New Search]
